Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tetrathiomolybdate (TM) promotes the dimerization of the metal-binding domain (WLN4) of the cellular copper efflux protein ATP7B through its characteristic sulfur bridge Mo2S6O2 cluster, and is used in the clinical treatment of Wilson’s disease.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | Tetrathiomolybdate (TM) promotes the dimerization of the metal-binding domain (WLN4) of the cellular copper efflux protein ATP7B through its characteristic sulfur bridge Mo2S6O2 cluster, and is used in the clinical treatment of Wilson’s disease. |
Molecular Weight | 224.2 |
Formula | MoS4 |
CAS No. | 16330-92-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
tetrathiomolybdate 16330-92-0 inhibitor inhibit